Expression of costimulatory molecule CD80 on peripheral blood T cells in patients with systemic lupus erythematosus
Takasaki, Y.; Ogaki, M.; Abe, K.; Takeuchi, K.; Ando, S.; Tokano, Y.; Kobayashi, S.; Sekigawa, I.; Tsuda, H.; Hashimoto, H.
Journal of Rheumatology 25(6): 1085-1091
1998
ISSN/ISBN: 0315-162X PMID: 9632068 Document Number: 486436
Objective. To investigate the expression of costimulatory molecule CD80 on T cells of peripheral blood mononuclear cells (PBMC) in patients with systemic lupus erythematosus (SLE). Methods. Monoclonal antibodies against CD80 were used for flow cytometry and expression of CD80 on PBMC was studied in 26 patients with SLE, 18 patients with rheumatoid arthritis (RA), 8 patients with mixed connective tissue disease (MCTD), and 22 healthy controls. Results. CD80 was detected on CD3+ and CD19+ cells in patients with SLE and it was significantly higher than that of controls. In patients with SLE CD80 was expressed on CD4+ T cells (8.05 +- 5.45%), significantly higher than in RA and controls, but was not highly expressed on CD8+ T cells (1.67 +- 2.87%). CD80+CD4+ T cell phenotype analysis revealed CD45RA-, CD45RO+, and CD25+, or HLA-DR+ activated T cells. The percentage of CD80+ cells in CD4+ cells increased in the active stage of SLE, and was significantly correlated with the SLE disease activity index. Conclusion. CD80 can be expressed on activated CD4+ T cells in PBMC of patients with SLE in vivo and the appearance of these cells is associated with the disease activity in SLE.